Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department

• Status: Completed
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if an 8hr infusion of nesiritide in the emergency department in the Acutely decompensated heart failure patients will decrease 30 day recidivism.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Collaborator: Scios, Inc.
• Treatments: Natriuretic Peptide, Brain; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Patients who were adults greater than 18 years of age

• A history of established heart failure

• Dyspnea at rest or with minimal exertion and with a respiratory rate greater than 24 breaths per minute

• Evidence of volume overload based on physical exam findings or chest radiograph, and a brain natriuretic peptide (BNP) level greater than 100 pg/ml.

Exclusion Criteria:

• Systolic blood pressure of less than 90 mm Hg

• Frank or impending cardiogenic shock

• Cardiopulmonary arrest

• Evidence of low cardiac output (cold clammy extremities

• Mental status changes)

• New onset congestive heart failure

• Suspected acute coronary syndrome (elevated troponin, New electrocardiographic changes, or history consistent with cardiac ischemia)

• High clinical suspicion of pulmonary embolism

• End-stage renal disease (on dialysis or imminent)

• Active use of nitroglycerin or inotropic infusions in the ED

• Ventricular tachycardia

• Allergy to nesiritide or its components

• Patient not needing intravenously diuretic therapy in the ED

• Normal BNP level

• Inability to follow-up

• Pregnancy or suspected pregnancy; or

• Actively receiving other investigational drug.